Insider Selling: Beigene, Ltd. (NASDAQ:ONC) CEO Sells 5,127 Shares of Stock

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 5,127 shares of the business’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $252.77, for a total transaction of $1,295,951.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Beigene Price Performance

NASDAQ:ONC opened at $263.42 on Wednesday. The company’s 50-day simple moving average is $238.58. Beigene, Ltd. has a fifty-two week low of $141.31 and a fifty-two week high of $287.88. The company has a market cap of $31.18 billion, a PE ratio of -31.97, a PEG ratio of 7.73 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.

Beigene (NASDAQ:ONC) last issued its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. On average, research analysts expect that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on ONC shares. Macquarie increased their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a research report on Thursday, March 13th. JMP Securities set a $348.00 price objective on Beigene in a research note on Friday, February 28th. Guggenheim raised their target price on Beigene from $348.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Finally, TD Securities reaffirmed a “buy” rating and set a $334.00 target price on shares of Beigene in a report on Thursday, April 24th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $319.00.

About Beigene

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.